Uwe Haberkorn
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Uwe Haberkorn's Heidelberg group developed the quinoline-based FAP inhibitor (FAPI) tracers that image most epithelial cancers and led early PSMA-617 and FAP-targeted therapy in humans.
| Title | Journal | Year |
|---|---|---|
| 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer | Journal of Nuclear Medicine | 2019 |
Pages like this
not linked directly; found by shared links- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares FAP-2286 (177Lu / 68Ga), Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
- PersonFrederik Giesel
Shares A university cyclotron network with shared regulatory files for new tracers, European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, FAPI PET.
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares FAP-2286 (177Lu / 68Ga), A university cyclotron network with shared regulatory files for new tracers, FAPI PET, FAP.
- PersonMichael Hofman
Shares A university cyclotron network with shared regulatory files for new tracers, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares German Cancer Research Center (DKFZ), FAPI PET, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- PersonClemens Kratochwil
Shares European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, PSMA.